“Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids”, J of Skin, vol. 8, no. 2, p. s397, Mar. 2024, doi: 10.25251/skin.8.supp.397.